- Resource
- BR1DGE
- Early Detection
- Video
Identifying Adult-onset T1D
Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.
Learning Objectives
- Recognize the clinical signs that may indicate adult-onset T1D, including younger age, lower body-mass index, and a personal or family history of autoimmune disease
- Understand how gestational diabetes mellitus can be an early indicator of underlying T1D autoimmunity, and when to consider autoantibody testing in this population
Summary
This video examines why distinguishing adult-onset type 1 diabetes (T1D) from type 2 diabetes (T2D) matters, and the opportunities to screen individuals with suspected autoimmune T1D. Prof Colin Dayan explains how identifying adult-onset T1D is challenging in practice, and why accurate classification is important. He goes on to highlight gestational diabetes mellitus as a setting in which underlying T1D autoimmunity should be considered. Prof Francesco Giorgino outlines features that should prompt consideration of T1D autoantibody testing in adults, including younger age, low body mass index, poor response to dietary restriction, and a personal or family history of autoimmune disease.
MAT-GLB-2601302 - 1.0 - 08/2026
Faculty Disclosures
Prof Colin Dayan
- Research funding: Charities and government/EU funding
- Speaker/Consultant: Vielo Bio, Provention Bio, Sanofi, Amarna, SAB Therapeutics, AstraZeneca, Shoreline Bio, Immunocore, Quell, Vertex
- Other: Patent held jointly with Biodexa PLC
Prof Francesco Giorgino
- Research funding: Eli Lilly, Roche Diabetes Care
- Speaker/Consultant: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi
- Other: President of European Association for the Study of Diabetes (EASD)/European Foundation for the Study of Diabetes (EFSD), and Vice Chair of the European Diabetes Forum (EUDF)
The Evolving Landscape of Early Detection in T1D
Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.
Communicating the Benefits of T1D Screening and Early Detection
Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.
Advancing Models of Care for People with Type 1 Diabetes
Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.